Results with 400 mg/d versus 600 mg/d in chronic myelogenous leukemia (CML) advanced phase patients.
| . | Accelerated23 . | Blast24 . | ||
|---|---|---|---|---|
| . | 400 mg . | 600 mg . | 400 mg . | 600 mg . |
| Abbreviations: d, day; HR, hematologic response; CHR, complete hematologic response; MCR, major cytogenetic response; TTP, time to progression. | ||||
| HR | 65% | 71% | 9% | 35% |
| CHR | 27% | 37% | 3% | 14% |
| MCR | 16% | 28% | 6% | 18% |
| TTP | 8 months | Not reached (P = 002) | ||
| 12-month survival | 65% | 78% (P = 0.014) | ||
| . | Accelerated23 . | Blast24 . | ||
|---|---|---|---|---|
| . | 400 mg . | 600 mg . | 400 mg . | 600 mg . |
| Abbreviations: d, day; HR, hematologic response; CHR, complete hematologic response; MCR, major cytogenetic response; TTP, time to progression. | ||||
| HR | 65% | 71% | 9% | 35% |
| CHR | 27% | 37% | 3% | 14% |
| MCR | 16% | 28% | 6% | 18% |
| TTP | 8 months | Not reached (P = 002) | ||
| 12-month survival | 65% | 78% (P = 0.014) | ||